Dr. Scott E. Delacroix

About Scott E. Delacroix

Education:

• Received MD (Doctor of Medicine) from Louisiana State University School of Medicine, New Orleans, in 1987.

Experience:

• Board Certified in Internal Medicine by the American Board of Internal Medicine.
• Currently practicing at LSU Healthcare Network / Metairie Multi-Specialty Clinic.

Area of expertise

Affiliated Hospitals

LSU Healthcare Network / Metairie Multi-Specialty Clinic

East Jefferson General Hospital

Clinical Trials Scott E. Delacroix is currently running

Stereotactic Radiation + Immunotherapy

for Kidney Cancer

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Recruiting1 award Phase 221 criteria

Radium-223 + Cabozantinib

for Kidney Cancer with Bone Metastasis

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.

Recruiting1 award Phase 216 criteria

More about Scott E. Delacroix

Other Doctors you might be interested in

Frequently asked questions